Duke-NUS partners Xylonix to optimise liposome formulations for Xylonix’ 010DS-Zn cancer drug. (IMAGE)

Duke-NUS Medical School

Duke-NUS partners Xylonix to optimise liposome formulations for Xylonix’ 010DS-Zn cancer drug.

Caption

Duke-NUS partners Xylonix to optimise liposome formulations for Xylonix’ 010DS-Zn cancer drug.

Credit

Duke-NUS photo courtesy of Vincent Tay Photography

Usage Restrictions

with credit

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.